The efficacy of prophylactic azithromycin on bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation
- 30 June 2015
- journal article
- clinical trial
- Published by Springer Nature in International Journal of Hematology
- Vol. 102 (3) , 357-363
Abstract
The aim of this study was to determine whether prophylactic azithromycin treatment prevents bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HCT). A series of 1187 patients who underwent HCT between December 1993 and November 2013 at our tertiary referral center in South Korea were enrolled. The median age of these patients was 39.0 years, and 668 (56.3 %) were men. Acute leukemia was the most common indication for HCT. During a median follow-up of 30.7 months after HCT, BOS was diagnosed in 82 patients (6.9 %) at a median of 12.3 months after HCT. One hundred patients received prophylactic azithromycin, of whom 12 developed BOS. BOS was significantly more frequent in patients who were treated with than without prophylactic azithromycin (12.0 versus 6.4 %, P = 0.036). Multivariate analysis revealed that a busulfan-based conditioning regimen (HR 2.73, 95 % CI 1.66–6.45) was the only independent predictor of BOS. The prophylactic use of azithromycin was not associated with the development of BOS by multivariate analysis. Although the present study had some limitations such as its non-randomized retrospective design, differences in baseline patient characteristics between the two groups, and the preference for azithromycin use at our hospital, our findings suggest that prophylactic azithromycin seems to not prevent the development of BOS in HCT recipients.Keywords
This publication has 24 references indexed in Scilit:
- Obliterative BronchiolitisNew England Journal of Medicine, 2014
- Factors associated with bronchiolitis obliterans syndrome and chronic graft‐versus‐host disease after allogeneic hematopoietic cell transplantationAmerican Journal of Hematology, 2013
- Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot studyTransplant International, 2011
- Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT—a randomized double-blinded placebo-controlled studyBone Marrow Transplantation, 2011
- A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantationEuropean Respiratory Journal, 2010
- De Novo Production of K-α1 Tubulin-Specific Antibodies: Role in Chronic Lung Allograft RejectionThe Journal of Immunology, 2008
- Sparing Effect by Montelukast Treatment for Chronic Graft Versus Host Disease: A Pilot StudyTransplantation, 2007
- Azithromycin Reduces Airway Neutrophilia and Interleukin-8 in Patients with Bronchiolitis Obliterans SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary studyEuropean Respiratory Journal, 2005
- Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomesTransplantation and Cellular Therapy, 2003